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Adoptive cell therapy using autologous TIL is a promising
immunotherapy for metastatic melanoma. This study was
aimed at finding predictive biomarkers in TIL patients,
using IHC and gene expression analysis on original tumors
used to expand TIL. The purpose was to find factors asso-
ciated with optimal TIL outgrowth from melanoma
tumors and ultimately clinical response to therapy. We
found a significant differences in CD8, CD4 and CD3
staining in the tumors between good TIL growers and
poor growers by IHC (p < 0.0001, respectively). Interest-
ingly, the CD8 expression in the original tumors also cor-
related with the percentage of CD8+ T cells in the final
TIL product after expansion. Using a new droplet digital
PCR assay using TCR Vb-specific primers called Quan-
TILfy™, we also found that good TIL growers had a
higher TCR Vb gene signal than samples from poor
growers (p = 0.008 Mann-Whitney test) suggesting that
this genetic test may be useful in selecting patients for TIL
therapy. Gene expression profiling of 595 immunologi-
cally-relevant genes found differences in a number of
genes in tumors of patients having good TIL growth ver-
sus poor TIL growth, such as CD8b and CD3δ, CD45RA,
ICOS, PD-1, STAT4. Interestingly, CD8 gene expression
was significantly correlated with immunosuppression
pathway genes, such as PD-L1, PD-1, FoxP3, and IDO that
was confirmed by IHC analysis. Strikingly, IHC analysis of
these markers in original tumors, together with CD8, were
also found to be predictive of overall survival (OS) after
TIL infusion. There were also differences in key genes in
tumors of clinical responders and non-responders to TIL
treatment. One gene, IRAK1, was particularly interesting
as it regulates NFkB signaling and pro-inflammatory cyto-
kine production associated with decreased anti-tumor
adaptive immunity. Both gene expression and IHC analysis
found an association between higher IRAK1 and decreased
OS and relapse-free survival after TIL infusion. In conclu-
sion, our IHC and gene profiling assays on archived tumor
samples have uncovered predictive biomarker signatures
identifying patients eligible for TIL therapy and who will
most likely benefit from TIL therapy, as well as possible
new tumor resistance pathways to immunotherapy for
melanoma that can be targets of novel combination thera-
pies to enhance TIL therapy.
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